Perspective Therapeutics, Inc. Common Stock CATX 深 滬
等待開盤 09-17 09:30:00 美东时间
3.27
-0.320
-8.91%
華盛通- 最 高3.685
- 今 開3.56
- 成交量 101.80万股
- 最 低 3.25
- 昨 收 3.59
- 總市值 2.43亿
- 52周最高 13.56
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 1.60
- 委 比 49.15%
- 總股本 7426.30万
- 歷史最高 37.90
- 量 比 1.22
- 振 幅 12.12%
- 歷史最低 1.60
- 每 手 1
- 風險率 4.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Perspective Therapeutics Says First Patient Dosed In New Cohort Of Phase 1/2a Trial Evaluating The Safety Of [212Pb]VMT01
First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-openedSEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics,
09-15 19:08
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Perspective Therapeutics announced the initiation of a new Phase 1/2a trial cohort evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy, for metastatic melanoma patients. The first patient received 3.0 mCi of [212Pb]VMT01 in combination with nivolumab, while the single-agent 3.0 mCi cohort was re-opened following positive safety reviews. The company aims to advance higher doses to explore therapeutic potential and synergies be...
09-15 11:00
Perspective Therapeutics Names Joel Sendek CFO As Juan Graham Departs
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as
09-04 19:24
Perspective Therapeutics Appoints Maya Martinez-Davis to Board
The latest announcement is out from Perspective Therapeutics ( ($CATX) ). On Se...
09-03 19:29
Perspective Therapeutics to Participate in Upcoming September Conferences
Perspective Therapeutics, Inc. announced that senior leadership will participate in upcoming conferences including the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and OPCO Targeted Radiopharmaceutical Therapies in Oncology Summit. The company, specializing in radiopharmaceutical treatments for cancers, utilizes the alpha-emitting isotope 212Pb to target cancer cells. Their "theranostic" approach combines imag...
08-26 11:00
Perspective Therapeutics Q2 EPS $(0.30), Inline, Sales $290.000K Beat $154.455K Estimate
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 76.47 percent decrease over losses of $(0.17) per share from the same period last
08-13 18:47
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
A Look Ahead: Perspective Therapeutics's Earnings Forecast
Perspective Therapeutics (AMEX:CATX) is preparing to release its quarterly earn...
08-13 04:02
Perspective Therapeutics Updates Radiopharmaceutical Platform Presentation
Perspective Therapeutics ( ($CATX) ) just unveiled an announcement. On August 1...
08-02 04:29
Perspective Therapeutics To Present Updated [212Pb]VMT-α-NET Cancer Therapy Data At ESMO Congress 2025
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the
07-25 00:46
